In vivo Administration of TLR9 Agonist Reduces the Severity of Experimental Autoimmune Encephalomyelitis. The Role of Plasmacytoid Dendritic Cells and B Lymphocytes.

In vivo Administration of TLR9 Agonist Reduces the Severity of Experimental Autoimmune Encephalomyelitis. The Role of Plasmacytoid Dendritic Cells and B Lymphocytes. CNS Neurosci Ther. 2014 Jun 16; Authors: Longhini AL, Santos MP, Pradella F, Moraes AS, Dionete AC, Andrade MD, Russini PG, Oliveira EC, de Paula RO, Morais GA, Fonseca ES, Farias AS, Santos LM PMID: 24931054 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24931054?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - June 16, 2014 Category: Neuroscience Authors: Longhini AL, Santos MP, Pradella F, Moraes AS, Dionete AC, Andrade MD, Russini PG, Oliveira EC, de Paula RO, Morais GA, Fonseca ES, Farias AS, Santos LM Tags: CNS Neurosci Ther Source Type: research

More News: Brain | Neurology | Neuroscience